Program
DN022150
A development code. Also written as “DN022150+AG( Stage I )” and “DN022150+AG(Stage II)”.
Its studies are mostly in Pancreatic Neoplasms, led by Qingfeng Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qingfeng Pharmaceutical Group | 22 open or running | phase 3since Jun 5, 2026 | Jun 5, 2026 | Jul 2028phase 3 · NCT07689539 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 5, 2026First studies: 2 phase 3 studies in Pancreatic NeoplasmsFirst studyNCT07656376, NCT07689539
Ahead
- Jul 2028Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07689539
- Feb 7, 2029Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07656376
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07689539Pancreatic Neoplasms | 3 | Not yet recruiting | Jul 2028 | 360 |
| NCT07656376Pancreatic Neoplasms | 3 | Not yet recruiting | Feb 7, 2029 | 465 |
How it is read
Names in the registry
- “DN022150”, 1 entry
- “DN022150+AG( Stage I )”, 1 entry
- “DN022150+AG(Stage II)”, 1 entry
Codes read as this program: DN022150.
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.